Phaseline

Companies › TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG)

TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TPD3310 injection–Phase 1Advanced Malignant Solid TumorsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07368127TPD3310 injectionPhase 1Advanced Malignant Solid TumorsOncologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.